Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Children treated for acute lymphoblastic leukemia (ALL) may lose vaccine-derived immunity against measles and chickenpox after chemotherapy, new research suggests. A study in Pediatrics found that ALL patients had significantly lower antibody levels compared to healthy peers — with older kids hit hardest. Experts say the findings make a strong case for revaccination after treatment, though the optimal timing and dosing still need further study.
Children who survive the most common childhood cancer may be left vulnerable to measles and chickenpox — even after completing routine vaccinations. A new study published in Pediatrics found that kids treated for acute lymphoblastic leukemia (ALL) had significantly lower antibody levels against both diseases compared to healthy children, likely because chemotherapy damages the immune cells that preserve long-term vaccine protection.
The effect was most pronounced in older children: those aged 10–17 who had received two vaccine doses showed lower antibody levels than younger kids who had received just one dose. On a brighter note, T-cell responses — another key arm of immune defense — remained comparable to healthy controls, suggesting some immune memory is preserved.
Key Takeaways:
Why it matters: With measles outbreaks rising in the US and globally, understanding vaccine immunity gaps in cancer survivors is increasingly urgent. These findings suggest clinicians should consider revaccination after ALL treatment — and that similar risks may exist for survivors of other childhood cancers.
